Active Smoking Before Liver Transplantation in Patients with Alcohol Use Disorder: Risk Factors and Outcomes.
alcohol use disorder
liver transplant
risk factors
smoking
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Aug 2020
21 Aug 2020
Historique:
received:
12
07
2020
revised:
04
08
2020
accepted:
18
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Tobacco use is more prevalent among alcohol liver disease (ALD) transplant patients and exerts harmful effects to the patient and to the graft. The aims of this study were to examine the impact of smoking status (nonsmoker, ex-smoker, active smoker) on patient survival and clinical outcomes, and to assess risk factors for active smoking before and after liver transplant (LT). An observational retrospective cohort study with 314 ALD patients undergoing LT from January 2004 to April 2016. Recipients were followed until April 2017 or death. Kaplan-Meier and Cox proportional hazards regression analyses were used to assess risk of mortality according to smoking status before LT. Smokers had a 79% higher risk of dying than those who had never smoked or quit smoking before LT. Ex-smokers had a greater survival probability (96.2%, 93.8%, 86.9%, and 83.1% at 1, 3, 5, and 10 years after LT) than active smokers until LT (96.0%, 85.6%, 80.0%, and 70.4%). Active smokers before LT with poor toxicity awareness had more than a twofold higher risk of mortality (Cox HR = 2.20, 95% CI: 1.05-4.58,
Identifiants
pubmed: 32825794
pii: jcm9092710
doi: 10.3390/jcm9092710
pmc: PMC7564808
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Generalitat de Catalunya
ID : CERCA Programme
Organisme : Instituto de Salud Carlos III
ID : JR19/00025
Déclaration de conflit d'intérêts
López-Pelayo, H. has received honoraria from Lundbeck and Teva, and travel grants from Otsuka, Lundbeck, and Exeltis. Colmenero, J. is advisory to Chiesi and speaker for Novartis, Chiesi and Astellas. None of these supports represents any conflict of interest with the information provided in this study. The rest of the authors have no conflicts of interest to disclose.
Références
Clin Transplant. 2017 Mar;31(3):
pubmed: 28039946
Gastroenterology. 2009 Dec;137(6):2010-7
pubmed: 19766646
Liver Transpl. 2017 Nov;23(11):1404-1414
pubmed: 28590598
PLoS One. 2017 May 30;12(5):e0178570
pubmed: 28558038
Medicine (Baltimore). 2019 Aug;98(31):e16701
pubmed: 31374062
Clin Liver Dis. 2019 Feb;23(1):115-126
pubmed: 30454826
Transplantation. 2015 Sep;99(9):1862-8
pubmed: 26308417
Liver Transpl. 2006 Dec;12(12):1791-8
pubmed: 16823833
Liver Transpl. 2009 Jun;15(6):648-55
pubmed: 19479809
J Am Coll Surg. 2009 Jun;208(6):1077-84
pubmed: 19476895
Transplant Proc. 2016 Jul-Aug;48(6):1920-6
pubmed: 27569923
World J Hepatol. 2016 Apr 28;8(12):533-44
pubmed: 27134701
Drug Alcohol Depend. 2010 Aug 1;110(3):177-82
pubmed: 20378281
Liver Transpl. 2005 Jun;11(6):679-83
pubmed: 15915490
Liver Transpl. 2004 Mar;10(3):412-7
pubmed: 15004770
Liver Transpl. 2018 Dec;24(12):1690-1698
pubmed: 30207421
Liver Transpl. 2008 Aug;14(8):1159-64
pubmed: 18668649
Scand J Gastroenterol. 2013 May;48(5):585-91
pubmed: 23506154
Best Pract Res Clin Gastroenterol. 2017 Apr;31(2):181-185
pubmed: 28624106
Gastroenterol Hepatol. 2019 Dec;42(10):657-676
pubmed: 31771785
Gastroenterol Hepatol. 2009 Mar;32(3):155-61
pubmed: 19232780
Am J Med. 2011 Feb;124(2):144-154.e8
pubmed: 21295194
J Gastrointest Surg. 2015 Dec;19(12):2223-7
pubmed: 26358276
Liver Transpl. 2019 Aug;25(8):1142-1154
pubmed: 30920118
Am J Epidemiol. 2009 Jan 15;169(2):153-60
pubmed: 19033524